Alkem Laboratories (ALKEM) | Stock Overview & Key Data
Alkem Laboratories Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹6,439.90 on September 9, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Alkem Laboratories
ALKEM
|
660.06B Large-cap | -0.42% | -2.77% | 0.21% | -5.16% | -2.37% | 9.29% | 55.87% | 68.61% | 282.49% | 247.69% | 247.69% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Torrent
TORNTPHARM
|
1.39T Large-cap | 2.12% | 2.23% | 5.56% | 19.07% | 17.04% | 40.54% | 146.00% | 215.51% | 578.42% | 2,737.14% | 10,046.95% |
|
Dr. Reddy's
DRREDDY
|
1.10T Large-cap | 0.31% | -4.28% | 0.20% | -0.09% | 2.08% | -6.39% | 29.74% | 20.69% | 112.36% | 310.53% | 902.28% |
|
Lupin
LUPIN
|
1.07T Large-cap | 0.83% | -0.14% | -0.76% | 8.63% | 8.10% | 14.69% | 176.15% | 98.45% | 56.65% | 418.49% | 2,332.69% |
Ownership & Short Interest
Calculate Your Alkem Laboratories Investment Returns
Long-Term Investment Performance Analysis
Alkem Laboratories stock price in Aug 2016 was ₹1,524.95, A ₹1,000.00 lump sum investment in Alkem Laboratories made 9 years ago would be worth approximately ₹3,497.82 today, representing a outstanding return of 249.78%. This translates to an annualized return (CAGR) of 13.53%.
9 Years 10 Months Investment Scenario (Aug 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ALKEM's 52-week high and low?
- In the last 52 weeks, Alkem Laboratories reached a high of ₹5,933.50 (on January 13, 2026) and a low of ₹4,716.20 (on July 10, 2025).
- What is the market cap and P/E ratio for ALKEM?
- Curious about Alkem Laboratories's size and valuation? Its market capitalization stands at 660.06B. When it comes to valuation, the P/E ratio (trailing twelve months) is 28.77, and the forward P/E (looking ahead) is 29.92.
- Does ALKEM pay dividends? If so, what's the yield?
- Yes, Alkem Laboratories is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.95%, and the company has paid an average of ₹46.00 per share annually over the past 3 years.
- Who are Alkem Laboratories's main competitors or similar companies to consider before investing?
When looking at Alkem Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Torrent
TORNTPHARM1.39T Healthcare Drug Manufacturers - Specialty & Generic 40.54% 146.00% Dr. Reddy's
DRREDDY1.10T Healthcare Drug Manufacturers - Specialty & Generic -6.39% 29.74% Lupin
LUPIN1.07T Healthcare Drug Manufacturers - Specialty & Generic 14.69% 176.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alkem Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Alkem Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.42%, the Debt to Equity ratio from the most recent quarter is 17.06, and its Gross Profit Margin stands at 65.94%.
- What is the recent revenue and earnings growth for ALKEM?
- Looking at Alkem Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR143B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.70%, and quarterly earnings saw a YoY growth of 1.60%.
- How much of ALKEM stock is held by insiders and institutions?
- Wondering who owns Alkem Laboratories stock? Company insiders (like executives and directors) hold about 62.91% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.86%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.